drugset / Trial / NCT06749457

A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)

NCT06749457 ↗

Phase 1/2 Recruiting 231 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).

Timeline

Start
2024-12-30
Primary completion
2027-04-02
Completion
2028-01-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7760 Unknown — Intravenous